Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) on behalf of shareholders who purchased securities during the specified Class Period, alleging securities fraud related to misleading statements and undisclosed adverse facts about the company's operations and business prospects [1][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who bought Charming Medical Limited securities between October 10, 2025, and November 12, 2025, with a deadline for filing a lead plaintiff motion set for February 17, 2026 [1]. - The lawsuit alleges that the defendants made materially false and misleading statements and failed to disclose significant adverse facts about the company's business and operations [4]. Group 2: Allegations of Fraud - The complaint claims that Charming was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [4]. - It is alleged that insiders or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [4]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price, rendering the defendants' positive statements materially misleading [4]. Group 3: SEC Involvement - On November 11, 2025, the SEC issued an order to halt trading of Charming securities due to potential manipulation linked to social media recommendations aimed at artificially inflating the stock price and trading volume [3].
Law Offices of Frank R. Cruz Encourages Charming Medical Limited (MCTA) Shareholders To Inquire About Securities Fraud Class Action